Sutilain API Manufacturers

General Description:

Sutilain, identified by CAS number 12211-28-8, is a notable compound with significant therapeutic applications. Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored odorless powder. One gram of sutilain powder contains 250,000 casein units of proteolytic activity. Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.

Indications:

This drug is primarily indicated for: Sutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular diseases. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Sutilain undergoes metabolic processing primarily in: This pharmacokinetic parameter is not relevant. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Sutilain are crucial for its therapeutic efficacy: Sutilain is not absorbed. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Sutilain is an important consideration for its dosing schedule: This pharmacokinetic parameter is not relevant. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Sutilain exhibits a strong affinity for binding with plasma proteins: This pharmacokinetic parameter is not relevant. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Sutilain from the body primarily occurs through: This pharmacokinetic parameter is not relevant. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Sutilain is distributed throughout the body with a volume of distribution of: This pharmacokinetic parameter is not relevant. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Sutilain is a critical factor in determining its safe and effective dosage: This pharmacokinetic parameter is not relevant. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Sutilain exerts its therapeutic effects through: Reports indicated that sutilain exhibited a rapid and effective debridement when used for the treatment of burns, decubiti and traumatic wounds. In the case of peripheral vascular ulcerations, it did not respond in a predictable manner. When used, sutilain caused a rapid dissolution of the surface of the treated skin zone. However, a graftable wound bed as achieved no more rapidly than if saline soaks had been used since the enzyme appears to be ineffective in removing deep dermal elements and necrotic fat. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Sutilain functions by: Sutilain is a proteolytic enzyme that dissolves necrotic tissue and hyaluronidase. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Sutilain belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.

Categories:

Sutilain is categorized under the following therapeutic classes: Endopeptidases, Enzymes, Enzymes and Coenzymes, Hydrolases, Peptide Hydrolases, Serine Endopeptidases, Serine Proteases. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.